Bio-Technology General Corp. Appoints Christopher G. Clement President, Chief Operating Officer.

Business Editors

ISELIN, N.J.--(BUSINESS WIRE)--April 24, 2002

Bio-Technology General Corp. (NASDAQ:BTGC) today announced that Christopher G. Clement, CEO and Chairman of Epicyte Pharmaceutical, Inc., a California-based company, has been appointed President and Chief Operating Officer.

He will assume his duties effective May 14, 2002. Mr. Clement succeeds Virgil Thompson who left BTG in 2000 but remains a member of the Board of Directors.

Mr. Clement, 46, has a career in the biopharmaceutical industry spanning more than 20 years that includes broad executive experience covering marketing and sales, strategic and product planning, business development, and general management. Prior to joining Epicyte in 2000, he held the positions of Executive Vice President and Senior Vice President, Chief Marketing Officer at Ares-Serono Group. From 1988 to 1997, Mr. Clement held a number of senior management positions at Searle Pharmaceuticals, including Vice President of Marketing, Vice President of Corporate Product Planning, Vice President, General Manager of Global Franchises, and Division President.

BTG Chairman and CEO Sim Fass said: "We are very pleased to welcome Mr. Clement to our management team. He has a highly successful track record and brings strong executive level experience across multiple disciplines to our Company. We believe he will be a very valuable asset to BTG, and we look forward to the contributions he will make to the leadership of our organization, its growth, and further success."

Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed worldwide. Products sold in the United States are Oxandrin(R) (oxandrolone, USP), marketed by BTG and by the Ross Products Division of Abbott Laboratories under a co-marketing agreement, Delatestryl(R) (testosterone enanthate), marketed by BTG, Mircette(R) (oral contraceptive), marketed by Organon, Inc., and BioLon(TM) (sodium hyaluronate), marketed by Akorn, Inc. Products sold internationally are Bio-Tropin(TM) (recombinant human growth hormone), BioLon(TM) (sodium hyaluronate), Bio-Hep-B(TM) (hepatitis B vaccine), Arthrease(TM) (sodium hyaluronate for osteoarthritis), and Silkis(R) (vitamin D derivative). BTG's news releases and other information are available on the Company's website at www.btgc.com.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.